AIM ImmunoTech (AIM) Non-Current Assets (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Non-Current Assets came in at $2.4 million in Q1 2026, down 35.29% YoY from $3.7 million in Q1 2025, and down 4.66% on a QoQ basis from $2.5 million in Q4 2025.
AIM ImmunoTech (AIM) Non-Current Assets (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Non-Current Assets data on file, last reported at $2.4 million in Q1 2026.
- Quarterly Non-Current Assets fell 35.29% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (down 44.11% YoY) and the FY2025 annual result came in at $2.5 million, down 43.89% from the prior year.
- Non-Current Assets fell to $2.4 million in Q1 2026, from $2.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $6.0 million in Q3 2024 to a low of $2.4 million in Q1 2026.
- A 5-year average of $4.2 million and a median of $4.4 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 83.49% — and 2024, when it increased 17.56%.
- Tracing AIM's Non-Current Assets over 5 years: stood at $4.2 million in 2022, then gained by 15.79% to $4.8 million in 2023, then slipped by 8.15% to $4.4 million in 2024, then sank by 43.89% to $2.5 million in 2025, then decreased by 4.66% to $2.4 million in 2026.
- The last three Non-Current Assets figures came in at $2.4 million (Q1 2026), $2.5 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.76 Bn | 130.91 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.15 Bn | 78.15 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.45 Bn | 59.27 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.08 Bn | 51.94 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.90 Bn | 27.59 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.76 Bn | 9.37 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 18.06 Bn |
| 10 | AIM ImmunoTech | 4.47 Mn | -5.50 Mn | 21,000.00 | 2.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.37 Mn |
| Dec 31, 2025 | 2.49 Mn |
| Sep 30, 2025 | 2.92 Mn |
| Jun 30, 2025 | 3.10 Mn |
| Mar 31, 2025 | 3.66 Mn |
| Dec 31, 2024 | 4.43 Mn |
| Sep 30, 2024 | 6.02 Mn |
| Jun 30, 2024 | 5.35 Mn |
| Mar 31, 2024 | 4.88 Mn |
| Dec 31, 2023 | 4.83 Mn |
| Sep 30, 2023 | 5.12 Mn |
| Jun 30, 2023 | 4.75 Mn |
| Mar 31, 2023 | 4.30 Mn |
| Dec 31, 2022 | 4.17 Mn |
| Sep 30, 2022 | 5.14 Mn |
| Jun 30, 2022 | 4.84 Mn |
| Mar 31, 2022 | 3.78 Mn |
| Dec 31, 2021 | 7.49 Mn |
| Sep 30, 2021 | 25.04 Mn |